Patents by Inventor Martin A. Maier

Martin A. Maier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10369226
    Abstract: The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: August 6, 2019
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Martin Maier, Muthusamy Jayaraman, Akin Akinc, Shigeo Matsuda, Pachamuthu Kandasamy, Kallanthottathil G. Rajeev, Muthiah Manoharan
  • Publication number: 20190211341
    Abstract: The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the TMPRSS6 gene, and methods of using such RNAi agents to inhibit expression of TMPRSS6 and methods of treating subjects having a TMPRSS6 associated disorder, e.g., an iron overload associated disorder, such as ?-thalassemia or hemochromatosis.
    Type: Application
    Filed: November 15, 2018
    Publication date: July 11, 2019
    Inventors: James Butler, Brian Bettencourt, Kallanthottathil G. Rajeev, Martin A. Maier, Klaus Charisse
  • Publication number: 20190184018
    Abstract: The present invention provides a phosphorothioate-modified oligonucleotide comprising a structure shown below: The present invention also provides a phosphorothioate-modified oligonucleotide comprising a structure having formula (CIII):
    Type: Application
    Filed: November 20, 2018
    Publication date: June 20, 2019
    Inventors: Muthiah MANOHARAN, Kallanthottathil G. RAJEEV, Jayaprakash NAIR, Martin MAIER
  • Publication number: 20190167800
    Abstract: The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells.
    Type: Application
    Filed: September 6, 2018
    Publication date: June 6, 2019
    Applicant: Arbutus Biopharma Corporation
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Muthusamy Jayaraman, David Butler, Jayaprakash K. Nair, Martin Maier, Laxman Eltepu
  • Publication number: 20190153443
    Abstract: This invention relates to methods for increasing the efficiency of siRNA administrations via pre-administration of an agent that lowers LDL receptor levels.
    Type: Application
    Filed: July 16, 2018
    Publication date: May 23, 2019
    Applicant: Arbutus Biopharma Corporation
    Inventors: Kevin Fitzgerald, Maria Frank-Kamenetsky, Akin Akinc, Martin A. Maier
  • Patent number: 10273478
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) targeting a PROC gene, and methods of using the dsRNA to inhibit expression of PROC.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: April 30, 2019
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Ivanka Toudjarska, John M. Maraganore, Brian Bettencourt, Stuart Milstein, Martin A. Maier, Klaus Charisse, Kallanthottathil Rajeev, Satyanarayana Kuchimanchi
  • Patent number: 10266484
    Abstract: The present invention relates to a cationic lipid having one or more biodegradable groups located in the mid- or distal section of a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
    Type: Grant
    Filed: May 15, 2017
    Date of Patent: April 23, 2019
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Muthiah Manoharan, Martin Maier, Muthusamy Jayaraman, Shigeo Matsuda, Jayaprakash K. Nair, Kallanthottathil G. Rajeev, Akin Akinc, Thomas A. Baillie
  • Patent number: 10246713
    Abstract: The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the TMPRSS6 gene, and methods of using such RNAi agents to inhibit expression of TMPRSS6 and methods of treating subjects having a TMPRSS6 associated disorder, e.g., an iron overload associated disorder, such as ?-thalassemia or hemochromatosis.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: April 2, 2019
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: James Butler, Martin Maier, Kevin Fitzgerald, Shannon Fishman, Donald Foster, Vasant Jadhav, Stuart Milstein
  • Patent number: 10238749
    Abstract: The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the angiotensinogen (AGT) gene, and methods of using such RNAi agents to inhibit expression of AGT and methods of treating subjects having an AGT-associated disorder, e.g., hypertension.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: March 26, 2019
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Donald Foster, Brian Bettencourt, Klaus Charisse, Gregory Hinkle, Satyanarayana Kuchimanchi, Martin Maier, Stuart Milstein
  • Patent number: 10233448
    Abstract: One aspect of the present invention relates to double-stranded RNA (dsRNA) agent capable of inhibiting the expression of a target gene. The sense strand of the dsRNA agent comprises at least one thermally destabilizing nucleotide, and at least one said thermally destabilizing nucleotide occurring at a site opposite to the seed region (positions 2-8) of the antisense strand; and the antisense strand of the dsRNA agent comprises at least two modified nucleotides that provide the nucleotide a steric bulk that is less than or equal to the steric bulk of a 2?-OMe modification, wherein said modified nucleotides are separated by 11 nucleotides in length. Other aspects of the invention relates to pharmaceutical compositions comprising these dsRNA agents suitable for therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA agents, e.g., for the treatment of various disease conditions.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: March 19, 2019
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Martin Maier, Don Foster, Stuart Milstein, Satya Kuchimanchi, Vasant Jadhav, Kallanthottathil Rajeev, Muthiah Manoharan, Rubina Parmar
  • Patent number: 10208307
    Abstract: The present invention provides iRNA agents, e.g., double stranded iRNA agents, that target the transthyretin (TTR) gene and methods of using such iRNA agents for treating or preventing TTR-associated diseases.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: February 19, 2019
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Tracy Zimmermann, Amy Chan, Vasant Jadhav, Martin Maier, Kallanthottathil G. Rajeev
  • Publication number: 20190038768
    Abstract: One aspect of the present invention relates to double-stranded RNAi (dsRNA) duplex agent capable of inhibiting the expression of a target gene. The dsRNA duplex comprises one or more motifs of three identical modifications on three consecutive nucleotides in one or both strand, particularly at or near the cleavage site of the strand. Other aspects of the invention relates to pharmaceutical compositions comprising these dsRNA agents suitable for therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA agents, e.g., for the treatment of various disease conditions.
    Type: Application
    Filed: October 19, 2018
    Publication date: February 7, 2019
    Inventors: Kallanthottathil G. RAJEEV, Tracy ZIMMERMANN, Muthiah MANOHARAN, Martin MAIER, Satyanarayana KUCHIMANCHI, Klaus CHARISSE
  • Publication number: 20180362978
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) targeting an APOC3 gene, and methods of using the dsRNA to inhibit expression of APOC3.
    Type: Application
    Filed: April 9, 2018
    Publication date: December 20, 2018
    Inventors: Brian Bettencourt, Kevin Fitzgerald, Stuart Milstein, Martin A. Maier, Klaus Charisse, Kallanthottathil Rajeev, Satyanarayana Kuchimanchi, Muthiah Manoharan, Tuyen Nguyen
  • Publication number: 20180346910
    Abstract: The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the Serpina1 gene, and methods of using such RNAi agents to inhibit expression of Serpina1 and methods of treating subjects having a Serpina1 associated disease, such as a liver disorder.
    Type: Application
    Filed: June 14, 2018
    Publication date: December 6, 2018
    Inventors: Alfica Sehgal, Klaus Charisse, Brian Bettencourt, Martin A. Maier, Kallanthottathil G. Rajeev, Gregory Hinkle, Muthiah Manoharan
  • Publication number: 20180326070
    Abstract: The present invention provides iRNA agents comprising at least one subunit of the formula (I): wherein: A and B are each independently for each occurrence O, N(RN) or S; X and Y are each independently for each occurrence H, OH, a hydroxyl protecting group, a phosphate group, a phosphodiester group, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, —P(Z?)(Z?)O-nucleoside, —P(Z?)(Z?)O-oligonucleotide, a lipid, a PEG, a steroid, a lipophile, a polymer, —P(Z?)(Z?)O-Linker-OP(Z??)(Z??)O-oligonucleotide, a nucleotide, an oligonucleotide, —P(Z?)(Z?)-formula (I), —P(Z?)(Z?)— or -Linker-R; R is LG, -Linker-LG, or has the structure shown below: LG is independently for each occurrence a carbohydrate, e.g.
    Type: Application
    Filed: November 20, 2017
    Publication date: November 15, 2018
    Inventors: Muthiah MANOHARAN, Kallanthottathil G. RAJEEV, Jayaprakash NAIR, Martin MAIER
  • Patent number: 10125369
    Abstract: The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the PCSK9 gene, and methods of using such RNAi agents to inhibit expression of PCSK9 and methods of treating subjects having a lipid disorder, such as a hyperlipidemia.
    Type: Grant
    Filed: December 5, 2013
    Date of Patent: November 13, 2018
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Anna Borodovsky, Kallanthottathil G. Rajeev, Kevin Fitzgerald, Maria Frank-Kamenetsky, William Querbes, Martin Maier, Klaus Charisse, Satyanarayana Kuchimanchi, Muthiah Manoharan, Stuart Milstein
  • Patent number: 10117941
    Abstract: The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: November 6, 2018
    Assignee: Arbutus Biopharma Corporation
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Muthusamy Jayaraman, David Butler, Jayaprakash K. Nair, Martin Maier, Laxman Eltepu
  • Publication number: 20180299492
    Abstract: The present embodiments relate to a measuring apparatus and an associated measurement method. The measuring apparatus is installed on a line and includes a sensing unit having a first and a second voltage divider for producing a first and a second measurement signal with a measurement transducer. The first and second measurement signals are each forwardable via a measurement line directly to a signal transducer. The signal transducer is supplied with power via a supply line by being switchably connected to the measurement transducer.
    Type: Application
    Filed: July 7, 2016
    Publication date: October 18, 2018
    Inventors: Martin Maier, Uwe Weiss
  • Publication number: 20180286564
    Abstract: The invention relates to a power converter module comprising a circuit board (7) in which an iron core (1) is integrated in recesses (6) of the circuit board (7), a winding with windings, forming a secondary circuit (8) of the power converter module, is arranged in or on the circuit board (7).
    Type: Application
    Filed: August 8, 2016
    Publication date: October 4, 2018
    Inventors: Wolfgang Feil, Martin Maier, Uwe Weiss
  • Patent number: 10072623
    Abstract: A decoupling element, for decoupling a fuel injection valve from a cylinder head, includes a body that, in the mounted state, surrounds a housing of the fuel injection valve. The body is fashioned to include a cylinder-side support region to be supported on the cylinder head, and a valve-side support region for supporting the fuel injection valve. When the fuel injection valve is supported at the valve-side support region, the body is loaded with pressure. Only the cylinder-side support region of the body is fashioned in the shape of a closed ring, which connects segments of the body distributed around a circumference. The decoupling element enables the reduction of the transmission of noise from the fuel injection valve to the cylinder head.
    Type: Grant
    Filed: September 24, 2013
    Date of Patent: September 11, 2018
    Assignee: ROBERT BOSCH GMBH
    Inventors: Michael Mayer, Martin Scheffel, Martin Maier, Michael Knorpp, Pablo Antonio Napal Jimenez